AAAAAA
Results:
1-11
|
Results: 11
Authors:
Vanhoefer, U
Harstrick, A
Achterrath, W
Cao, SS
Seeber, S
Rustum, YM
Citation: U. Vanhoefer et al., Irinotecan in the treatment of colorectal cancer: Clinical overview, J CL ONCOL, 19(5), 2001, pp. 1501-1518
Authors:
Bacher, G
Nickel, B
Emig, P
Vanhoefer, U
Seeber, S
Shandra, A
Klenner, T
Beckers, T
Citation: G. Bacher et al., D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity, CANCER RES, 61(1), 2001, pp. 392-399
Authors:
Wilke, H
Vanhoefer, U
Rougier, P
Van Cutsem, E
Wils, JA
Baron, B
Citation: H. Wilke et al., Standard chemotherapy for gastric carcinoma: Is it a myth? In reply, J CL ONCOL, 18(23), 2000, pp. 4002-4003
Authors:
Vanhoefer, U
Rougier, P
Wilke, H
Ducreux, MP
Lacave, AJ
Van Cutsem, E
Planker, M
Dos Santos, JG
Piedbois, P
Paillot, B
Bodenstein, H
Schmoll, HJ
Bleiberg, H
Nordlinger, B
Couvreur, ML
Baron, B
Wils, JA
Citation: U. Vanhoefer et al., Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group, J CL ONCOL, 18(14), 2000, pp. 2648-2657
Authors:
Vanhoefer, U
Citation: U. Vanhoefer, Docetaxel in the first- and second-line therapy of gastric cancer, ONKOLOGIE, 23, 2000, pp. 40-42
Authors:
Vanhoefer, U
Achterrath, W
Wilke, H
Seeber, S
Citation: U. Vanhoefer et al., Preclinical evaluation of irinotecan, ONKOLOGIE, 23, 2000, pp. S2-S7
Authors:
Wilke, H
Vanhoefer, U
Achterrath, W
Stahl, M
Citation: H. Wilke et al., Irinotecan: New results in the combination chemotherapy of colorectal cancer, ONKOLOGIE, 23, 2000, pp. S8-S14
Authors:
Vanhoefer, U
Schleucher, N
Klaassen, U
Seeber, S
Harstrick, A
Citation: U. Vanhoefer et al., Ifosfamide-based drug combinations: Preclinical evaluation of drug interactions and translation into the clinic, SEMIN ONCOL, 27(1), 2000, pp. 8-13
Authors:
Yin, MB
Guo, B
Vanhoefer, U
Azrak, RG
Minderman, H
Frank, C
Wrzosek, C
Slocum, HK
Rustum, YMN
Citation: Mb. Yin et al., Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a noveltopoisomerase I inhibitor BNP1350, MOLEC PHARM, 57(3), 2000, pp. 453-459
Authors:
Vanhoefer, U
Harstrick, A
Kohne, CH
Achterrath, W
Rustum, YM
Seeber, S
Wilke, H
Citation: U. Vanhoefer et al., Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer, J CL ONCOL, 17(3), 1999, pp. 907-913
Authors:
Vanhoefer, U
Muller, MR
Hilger, RA
Lindtner, B
Klaassen, U
Schleucher, N
Rustum, YM
Seeber, S
Harstrick, A
Citation: U. Vanhoefer et al., Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines, BR J CANC, 81(8), 1999, pp. 1304-1310
Risultati:
1-11
|